source
- Eli Lilly to pay up to $2.3B for Ajax's JAK inhibitor in cancer dealEli Lilly announced a new agreement with Ajax Therapeutics to acquire rights to a JAK inhibitor called Kyle LaHucik for cancer treatment. The transaction could be worth up to $2.3 billion, reflect…
- Compass Therapeutics reports secondary endpoint data from pivotal biliary tract cancer trial, shares stock dropCompass Therapeutics announced new secondary‑endpoint results from its pivotal bispecific antibody trial in second‑line biliary tract cancer, a year after reporting a Phase 2/3 success. The additi…